A Phase I/II trial demonstrated that vaccination with DCs containing either telomerase and HLA-A2 binding peptides or tumor lysate in combination with IL-2 resulted in stable disease for 8 weeks in 48% of patients with mRCC [204]. This evidence concerns the gene IL2 and neoplasm.